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Abstract
Background: Previously we treated patients with insect sting allergy with venom immunotherapy
(IT) using whole body insect extracts. From 1980 we changed to insect venoms. The purpose of
this study was to analyse data from the patients in order to improve our treatment.
Methods: This is an open, single centre study on patients treated with venom IT 14 years or older
with a history of a systemic allergic reaction to an insect sting, a positive skin prick test (SPT) or a
positive RAST and willingness to comply with five years of IT. Clinical and laboratory data were
registered prospectively at the start of IT and after five years of treatment until 2003 on patients
who started IT between 1980 and 1998. Questionnaires were answered in 1989, 1993 and 2003.
Statistical analysis was done with Pearson's chi square, Fisher's exact or the t-test.
Results: Of 315 patients treated, 44 were given bee, 248 common wasp and 23 both venoms. Of
the common wasp sting incidents 5.5 % resulted in a severe allergic reaction (SAR) during adequate
IT and 22% after cessation. Seventy-one per cent of the patients carried epinephrine. Precautionary
steps were taken by 77% of the patients during or after inadequate IT. On or after adequate IT 83%
felt completely or substantially safe. Surprisingly 29 % of those inadequately treated felt safer and
50% were satisfied with having had the opportunity to be treated. The SPT became negative in 68%
of the wasp allergic patients after five years of adequate IT. Increased risk of experiencing SAR to
a future sting in wasp allergic patients after cessation of adequate IT was significantly associated with
a SAR due to IT during the rush regimen. SAR due to IT occurred very rarely during maintenance
dosing.
Conclusion: Adequate venom IT is very effective while ongoing but somewhat less effective after
cessation, while inadequate treatment gives poor results. More of our patients should complete
five years of IT and some should continue IT. The type of reaction to IT during incremental dosing
may be of help in deciding who should continue beyond five years. Maintenance IT may be taken
over by the general physician.
Background
After the study of Hunt et al [1] was published in 1978
showing the ineffectiveness of whole body insect extracts,
we stopped using whole body insect extracts in the
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treatment of patients with insect sting (hymenoptera)
allergy. When venom from bee and common wasp (vesp-
ula sp) became available in Norway in 1979, we started
skin testing patients allergic to insect stings and thereafter
treating those who had a positive skin prick test (SPT) or
positive specific IgE reaction (RAST) with immunotherapy
(IT) using insect venoms.
The purpose of this study was to examine the short and
long term effectiveness; side effects; causes for cessation of
IT; the serological data and the SPT results and quality of
life of our insect sting allergic patients, in order to help us
improve our treatment. The patients started IT between
1980 and 1998. The results from the first eight years of
treatment were published in 1988 [2], and are incorpo-
rated in the present study.
Materials and methods
In Norway there are about 20 different species of wasps,
of which vespula vulgaris and germanica (common
wasps) are frequently seen. Vespa crabro has not been
observed in Norway [3]. From a previous study we found
that we could use venom from common wasp (vespula
sp) as the sole wasp venom to our wasp allergic patients
[3]. In 1979 we established the concentration that dis-
criminates insect sting allergic patients from normal indi-
viduals and found this to be 100 microgram pr. ml for the
SPT and 1 microgram pr ml for the intracutaneous test
(IC) [4] the latter corresponding to data from the study of
Hunt et al [5]. We found the sensitivity to be almost equal
for both tests [4] and as SPT is the preferred method for
skin testing in Norway, we chose SPT as the standard
method
Patients who had a history of an immediate systemic aller-
gic reaction, with vascular and/or respiratory symptoms,
angioedema of the head and neck or symptoms from two
organ systems, to a sting from bee and/or wasp and who
were willing to comply with a minimum of five years of
treatment were offered IT. The SPT or RAST reaction had
to be positive to the respective venom. For SPT we used
Pharmalgen (ALK) venoms at 100 microgram pr. ml con-
centration and Soluprick (ALK) for inhalant allergens.
Histamine chloride served as reference, 1 mg/ml for insect
venoms during the whole study. For the first five years of
the study the commercially available SPT test for inhalant
allergens used 1 mg/ml histamine as reference and later
10 mg/ml. The concentration of the inhalant allergens
was adjusted accordingly. If the size of the wheal of the
SPT area was 50% or larger than that caused by histamine
and had a minimum diameter of 3 mm larger than the
control, it was recorded as positive. Serum analyses of
total and specific IgE were done at a laboratory using
Pharmacia RAST from 1980 to1987, CAP from1988
to1998 and DCP Alastat from 1999 to 2003. In addition
analyses of haemoglobin, leukocytes, CRP, creatinine,
ASAT, ALAT and serum electrophoresis were undertaken.
Serum tryptase was not analysed, however none of the
patients had urticaria pigmentosa. The IT was performed
with Pharmalgen (ALK) venoms. The injections were
given subcutaneously on the lateral part of the upper arm.
Aspirations were done at the beginning and during the
injection. We used a rush regimen of five days duration
giving a starting dose of 0.1 microgram venom, doubling
this every 2 hours for three days. The dose was increased
more slowly on day four and five aiming for 50 micro-
grams or more for the last injection. Thereafter the venom
was given at weekly intervals gradually increasing the dose
to 0.1 mg and the interval to six weeks. Seven patients
received Alutard (ALK) venoms. Many patients were
referred back to their general practitioner to continue the
IT after having reached 0.1 mg as their maintenance dose.
A few patients who only tolerated 50 micrograms venom
used this as their maintenance dose even if this is less
effective. If they did not tolerate 50 micrograms of venom
after up to three years of IT, the treatment was ended.
Patients who tested positive to both bee and common
wasp venoms were treated with both venoms. Beekeepers
and their relatives who were allergic to bee stings were not
given IT if they abandoned bee keeping and there was no
bee keeping within 10 km. Patients were instructed to
keep epinephrine at hand and for those who had not
reached the dose of 0.1 mg venom, to inject it immedi-
ately after a sting. Having reached this dose they should
only inject if symptoms occurred.
Five years after the start of IT the patients were asked to
return for clinical examination, SPT and serological tests,
regardless of status of completion of IT. Many patients
also met for an extra consultation at a later date for the
same procedures. Information was also obtained at the
time of renewal for prescription of venom. Question-
naires asking for the patients reactions to stings, and reac-
tion to and length of IT were answered by mail and/or by
telephone interview in 1989, 1993 and 2003. The 2003
questionnaire also included questions on precautionary
steps and safety feeling. We divided our patients into two
groups according to the duration and dosage of the IT. IT
is considered adequate if the maintenance dose is 0.1 mg
venom and at cessation has lasted a minimum of five
years. It is inadequate when the dose is less than 0.1 mg or
at cessation of a shorter duration than five years. SAR
(serious allergic reaction) is defined as a respiratory and/
or vascular reaction with an additional feeling of impend-
ing disaster or other serious symptom or requiring treat-
ment with epinephrine.
Statistical analysis was done with Pearson's chi square or
Fisher's exact test. For the duration of IT two samples t-test
was used.Clinical and Molecular Allergy 2005, 3:12 http://www.clinicalmolecularallergy.com/content/3/1/12
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Results
Three hundred and fifteen patients were included in the
study, 151 males (48%) and 164 females (52%). The age
varied from 14 to 73 with a mean of 41.1 years. Forty four
patients (14%) were given bee, 248 (79%) common wasp
(vespula sp.) and 23 (7%) both venoms. Table 1 shows
the most serious symptom the patients had experienced
from a sting.
According to the classification of Mueller, 306 were classi-
fied as having a grade three or four and nine a grade two
or lower reaction. We have grouped together grades three
and four as we in many cases found it difficult to ade-
quately classify the patients from the case histories. In
stead we tried to differentiate whether the reaction was
vascular, respiratory or combined vascular-respiratory
(Table 1). The SPT for inhalant allergy was positive in 32.5
% of the patients, but only 21% reported having a respira-
tory allergy.
Up to 2003 twenty one patients have died of causes unre-
lated to insect allergy. Information regarding these
patients obtained prior to their deaths is included in the
results. At the five years recall 92.2% met for consultation
and an additional 43.9% at a later date. The response rate
to the questionnaires was 98.3% in 1989, 90.7% in 1993
and 88.6% in 2003.
Several patients have experienced a reaction to the venom
injections. Their most serious reaction during incremental
dosing and during maintenance is recorded in Table 2.
Nearly half of the patients had a reaction and 23.5% a sys-
temic allergic one. SAR occurred more than once in a few
Table 1: Main Symptom
Insect\Symptom Vascular and respiratory Vascular Respiratory Angioedema head/neck Skin + gastrointest. Total
Bee 12 18 13 1 44
Common wasp 87 110 46 3 2 248
Bee/common wasp 6 8 6 3 23
Total 105 136 65 7 2 315
Table 2: Number of patients reacting to immunotherapy
Type of reaction During incremental dosing During maintenance dosing
Large local reaction 14 5




Joint / muscle pain 21 26
Tachycardia 10 1
Total 170 65
Table 3: Causes for cessation of immunotherapy before 5 years. 
Number of patients
Problems due to work or change of domicile 15
Reactions to immunotherapy 36
Other serious illness 7
Death of other causes 1
Own initiative 11
Tolerated multiple stings 1
Others 6
Total 77




Never drinking/eating outdoors 73
Never hiking alone 46
Always window screen 17
Mobile phone present 6
Others 16
Unknown 47Clinical and Molecular Allergy 2005, 3:12 http://www.clinicalmolecularallergy.com/content/3/1/12
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patients although we adjusted further dosing carefully.
SAR occurred in 45 patients 14.2% (12 males, 33 females)
(33 allergic to wasp, and 12 to bee) during increasing
dosing.
Several patients experienced joint or muscle pain. In five
cases swelling of joints was related to the injections disap-
pearing later but sometimes steroids were given to allevi-
ate the symptoms. In other cases rheumatoid arthritis or
osteoarthritis proved to be the cause of these symptoms.
During maintenance dosing SAR in one bee allergic
patient occurred when an attempt was made to increase
the dose above 0.1 mg, in one wasp allergic patient due to
a higher than planned dose after a prolonged interval of
IT, in one patient who received both venoms at the second
maintenance dose, in one wasp allergic patient after a few
maintenance doses and in one case there was an
unexplained syncope one day later. In three of these cases
there was a change in allergic sensitivity so that it was
impossible later to reach an adequate maintenance dose
again and IT was abandoned.
Seventy-seven patients (24%) did not complete the mini-
mum of five years of IT. The reasons for stopping treat-
ment before five years are given in Table 3. The most
serious reaction causing cessation occurred in a female
patient who had a cardiac arrest without prior warning at
day four, 20 minutes after receiving 30 microgram com-
mon wasp venom as the second dose that day. It was dif-
ficult to resuscitate her, but she has recovered completely.
Table 5: Feeling of safety. Number of patients
Adequate treatment Inadequate treatment Total
Complete 54 4 58
Substantially 118 14 132
Somewhat 21 19 40
None 14 24 38
Unknown 28 19 47
Total 235 80 315
Table 6: Worth the effort. Number of patients
Adequate treatment Inadequate treatment Total
Yes 192 31 223
No 11 29 40
Unknown 32 20 52
Total 235 80 315
Table 7: Reaction to sting in common wasp allergic patients during IT. Number of times stung
Type of reaction Inadequate dosage Adequate dosage
No / local swelling 7 (1) 132 (23)
Sedation 2 (1) 25 (10)
Itching / urticaria etc. 0 7
SAR 14 (14) 9 (7)
Joint / muscle pain 0 3 (3)
Tachycardia 0 2 (1)
Total 23 (16) 178 (44)
In parenthesis number of times adrenaline was administered.Clinical and Molecular Allergy 2005, 3:12 http://www.clinicalmolecularallergy.com/content/3/1/12
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Another patient received the dose accidentally in an intra-
venous drip. In the group other causes for stopping IT one
was a patient afraid of acquiring AIDS from the venom
injections and three patients afraid of receiving injections
during pregnancy although we recommended
continuation.
Eighteen patients are still treated.
Seventy one per cent of the patients keep epinephrine at
hand. No difference was seen whether or not the patients
had completed five years of treatment. Of those inade-
quately treated 76 % take precautionary steps to avoid
being stung, whereas only 57.4% of those adequately
treated do so. Table 4 lists the different precautionary
steps taken.
In Table 5 the feeling of safety as experienced by the
patients according to the status of their IT is shown.
Eighty-three per cent of the adequately treated patients
feel completely or substantially safe and surprisingly 29%
of the inadequately treated. Those who feel unsafe
although having completed adequate IT had either experi-
enced a SAR to a sting during treatment or were discour-
aged by having a positive SPT reaction at the fifth year,
even if informed that this is not uncommon. Ninety-four
per cent of the adequately treated patients found the
investment in time, expenses and effort worthwhile
(Table 6). Those who did not benefit from the IT regarded
the inconvenience of IT as bothersome.
Reactions to field stings during treatment in patients aller-
gic to common wasp as reported by the patients are pre-
sented in Table 7. The number of stings per incident was
low, usually only one and never more than four. We have
recorded the reactions to each incident regardless of the
number of stings. SAR occurred in 55% of the incidents
when the venom dose was below 0.1 mg. At full mainte-
nance dosing (0.1 mg venom) only 5.5% of the incidents
resulted in a SAR. Epinephrine was self administered in
most cases of SAR and also in some cases where no
reaction occurred (table 7). A few times the reaction
occurred so rapidly that the patients did not have time
enough to administer it. In bee allergic patients six of 13
patients had a SAR while inadequately treated, but only
one of 14 in adequately treated ones. In addition two bee-
keepers had multiple stings without reaction.
We have also registered the reactions to stings after cessa-
tion of IT. In inadequately treated patients SAR occurred
in 19 of 45 (42%) of the sting incidents in wasp allergic
patients and in four of 19 (21%) in bee allergic ones. After
cessation of adequate IT in common wasp allergic patients
(Table 8) SAR occurred in 22% of all the sting incidents.
The reaction rate was higher after five years of cessation.
None of the bee allergic patients experienced a SAR after
cessation of IT.
The SPT became negative in 68% of the patients allergic to
common wasp having completed adequate IT, and only in
42% of inadequately treated ones (Table 9). For bee aller-
gic patients the SPT became negative in 74.3% of the ade-
quately treated ones.
Total IgE did not change appreciably during the five years,
see Table 10.
No changes that could be attributed to the IT were seen in
haemoglobin, creatinine, ASAT, ALAT, CRP or serum
electrophoresis.
Table 11 lists a comparison between those who did not
experience any reaction to a sting after cessation of ade-
quate IT (group A) and those who experienced a SAR
(group B) in patients allergic to common wasp. A
statistical analysis was made on the following data, age,
gender, symptom at inclusion, SPT to inhalant allergens,
SPT, RAST and total IgE at five years of treatment, reaction
due to incremental IT and duration of IT, to assess the
prognostic value for a SAR to future stings after cessation
of IT. Only the reaction to IT during incremental dosing
Table 8: Reaction to sting after adequate immunotherapy of 5 or more years' duration in common wasp. Number of times stung
Type of reaction 0–5 years after cessation More than 5 years after cessation Total
No / local swelling 61 (3) 14 75 (3)
Itching / urticaria etc. 5 (2) 0 5 (2)
Sedation 7 (3) 1 8 (3)
SAR 19 (11) 7 (5) 26 (16)
Joint pain 0 0 0
Tachycardia 4 (1) 0 4 (1)
Total 96 (20) 22 (5) 118 (25)
In parenthesis: Number of times adrenaline was administered.Clinical and Molecular Allergy 2005, 3:12 http://www.clinicalmolecularallergy.com/content/3/1/12
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had a prognostic value in assessing the reaction to a future
sting.
Discussion
This study was started in 1980 and was ongoing for many
years. However the main author has been in charge during
the whole period. The clinical information and laboratory
data have been continuously registered. Some of the test
procedures have changed. At the start the SPT kits con-
tained histamine 1 mg/ml as reference and inhalant
allergens corresponding to that (1 HEP). In 1985 hista-
mine 10 mg/ml and allergens corresponding to this (10
HEP) became standard. As we have graded the reaction
according to the corresponding reference, we believe that
the results are comparable for inhalant allergens. As we
chose to use 0.1 mg venom as basis for the SPT, we con-
tinued to use histamine 1 mg/ml as reference and we have
therefore been able to compare the test results throughout
the years.
The RAST results however may not be directly comparable
as the laboratory changed their methods. The CAP system
is more sensitive than the original RAST [6] so that the
conversion factor from this study was used. The DPC Ala-
Stat method has in unpublished data in-house shown to
be comparably sensitive to CAP.
It is estimated that in the Nordic countries a patient in
average gets a sting every tenth year [4,6]. That means that
the untreated patient would expect SAR to several future
stings.
This study has shown that ongoing IT for common wasp
is very efficient when the maintenance dose is 0.1 mg, as
also seen in other studies [1,8] and for bee even better
than others [9]. The results may have been slightly differ-
ent as some patients who did not experience any reaction
to a sting still injected epinephrine.
We strive to get as high a percentage of patients to com-
plete five years of IT as seen in other studies [10] because
the results of our inadequately treated patients are poor
and do not seem to differ from untreated ones [11]. After
cessation of IT the results for inadequately treated patients
are unfavourable compared to adequately treated ones.
However, the adequately treated wasp allergic patients
experienced a SAR to sting after cessation of IT more fre-
quently than has been found in other studies [12]. We
have no explanation for this. Some of the patients should
therefore preferable continue IT indefinitely. Such selec-
tion is difficult. According to other studies the following
symptoms and signs have been found to be risk factors for
experiencing SAR at a future sting after cessation of ade-
quate IT [13]: severity of pre-treatment reaction, safety
Table 9: SPT at start and after 5 years in bee and wasp allergic patients
Bee-allergic SPT grading
Year Neg. Pos. Total
00 + 0 40+23 40+23 = 63
52 9 + 11 10+11 39+22 = 61
Wasp-allergic
Year Neg. Pos. Total
01 2 0 8 + 43 209+43 = 252
51 4 2 + 18 67+25 209+43= 252
Italics: Number of patients incompletely treated.
Table 10: Total IgE. Patients allergic to common wasp
kU/ml < 122 123 – 300 > 300 Total
Year: 0 132 + 26 29 + 8 15 + 7 176 + 41 = 217
Year: 5 131 + 27 24 + 8 21 + 5 176 + 40 = 216
In italics: Number of patients incompletely treated.Clinical and Molecular Allergy 2005, 3:12 http://www.clinicalmolecularallergy.com/content/3/1/12
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and efficacy of IT, duration of IT, and high sensitivity with
the IC test. Specific IgE has in some but not all studies
[13,14] been found predictive. We, however, have only
found SAR due to IT during incremental dosing to be sig-
nificantly predictive. Using this criterion we may be able
to offer continued IT to some patients and still keep the
total number treated low. The rest of the patients will have
to rely on epinephrine.
Epinephrine offered as the only treatment instead of IT
seems to reduce quality of life [15]. This has also been
found when recommended to patients given IT [16]. We
believe that carrying epinephrine is a sound safety
precaution as our data show that the patients were able to
use it when needed. We are satisfied that a majority of our
patients carry epinephrine and feel completely or substan-
tially safe even carrying epinephrine. This has fortunately
also been seen in other studies [17,18].
We have encountered several side effects during IT. The
percentage of patients with a systemic reaction during
incremental dosing is comparable to the EAACI multi-
center study [19] although we did not pretreat our
patients with antihistamines. The percentage of patients
experiencing a SAR during incremental dosing is higher.
One reason for this may due to the higher percentage of
females in this study as the reaction rate to IT in females
was higher than in males in this and the other study [19].
Our rush regime leads to a high accumulated dose on the
fourth or fifth day. This was in another study [20] found
to be a cause for serious reactions. We therefore planned
to modify our IT schedule on day four and five to reduce
the number of reactions. However, venoms are presently
only available in depot extracts in Norway. The very few
reactions during normal adequate venom maintenance
dosing allows us to continue our practice of having the
patients' local physicians continue the IT if they take the
necessary precautions.
Besides the allergic reactions we found sedation (fatigue)
and particularly joint and muscle pain to be an obstacle to
further IT. Headache and fatigue is well known [21] but
did not lead to cessation of IT in our study, although some
patients had to abstain from work on the day of injection
and sometimes also the next day. Little attention has been
paid to joint/muscle pain which in this study led to cessa-
tion of IT in some cases. Although we suspect this to be an
immune disease, we were unable to confirm it.
A large majority of the patients felt that the investment in
time, effort and expenses was worthwhile if they com-
pleted IT. This is comparable to reports by Oude Elbrink







No. % No %
Age ≤ 29 10 20 1 6 0.434
3 0 – 5 9 3 46 81 48 2
≥ 60 6 12 2 12
Gender Male 33 66 9 53 0.391
Female 17 34 8 47
Inclusion symptom Vascular 20 40 6 35 0.731
Respiratory 13 26 3 17 0.485
Inclusion symptom Vascular + respiratory 16 32 8 47 0.38
SPT pos. inhalation allergens 15 30 6 35 0.684
Reaction to rush regimen No / local swelling 29 58 7 41 0.020
SAR 4 8 6 35 0.013
Pos. SPT to venom 5 th year 16 32 9 53 0.123
Venom RAST, pos. 5 th year 26/48 54 11/14 79 0.129
Total IgE ≥ 123, 5 th year 9/44 20 6/14 43 0.158
Duration of IT in years 7.1 (5–15) 6.5 (5–10) 0.156
A: Patients allergic to common wasp who have had a minimum of 5 years of immunotherapy at full dose and have not had any reaction to 
subsequent stings.
B: Patients allergic to common wasp, who have had at least 5 years of immunotherapy at full dose, but after cessation have had serious reactions to 
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et al. [18] and Røsjø et al. [17]. Surprisingly 50% of those
that did not complete adequate IT also felt so. We believe
that these patients were grateful for having had the oppor-
tunity to be treated even though it was not adequate.
Conclusion
Ongoing venom IT is very effective when adequately per-
formed and the majority of patients feel substantially
safer. Most of them found the effort very worthwhile. We
should endeavour to get more of the patients to complete
five years of IT as the results both while ongoing and after
IT is much better for the adequately than for the inade-
quately treated patients. Still after cessation of adequate IT
22% of the wasp sting incidents resulted in a SAR. Fortu-
nately the majority of patients keep epinephrine at hand
and were able to use it when needed. Maintenance IT of
0.1 mg of single venom may be taken over by the general
physician. Only the following parameter, the reaction to
IT during incremental dosing was statistically significant
for predicting the reaction to a future sting after cessation
of adequate IT. This may help in deciding whether a
patient should continue IT after five years or not.
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